论文信息 - PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. - 字舞流文

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

J. Lee | R. Kurzrock | Vanda M. Stepanek | F. Janku | A. Naing | D. Hong | J. Wheler | S. Piha-Paul | A. Tsimberidou | R. Luthra | G. Falchook | S. Fu | J. Jack Lee | J. Lee | David S. Hong | Apostolia M. Tsimberidou | Vanda M. Stepanek | Sarina A. Piha-Paul | David S Hong | J. J. Lee